Cellular Reprogramming Reaches the Clinic: Inside ER-100, the First Human Trial to Rewind Aging Inside the Eye

For more than a decade, the idea that you could take an old cell and persuade it to behave like a young one has lived almost entirely in mouse cages and petri dishes. That changed quietly at the end of January 2026, when the U.S. Food and Drug Administration cleared an investigational new drug application for a gene therapy called ER-100. With that single regulatory decision, partial epigenetic reprogramming, one of the most ambitious and most controversial ideas in modern aging biology, finally crossed from the laboratory into a human being.

Presented By Our Partners

ER-100 is the work of Life Biosciences, a Boston company co-founded by Harvard Medical School geneticist David Sinclair. The therapy does not try to kill aging cells, supplement a declining molecule, or edit a faulty gene. It attempts something stranger and more fundamental: to reset the software that tells a cell how old it is. The first patients will not be otherwise healthy people seeking to live longer. They will be people losing their sight. And that choice, as much as the science itself, explains why this trial matters.

What Partial Reprogramming Actually Is

To understand ER-100, you have to start with a problem that won Shinya Yamanaka the 2012 Nobel Prize. In 2006, Yamanaka showed that four transcription factors, later nicknamed the Yamanaka factors, could turn an ordinary adult cell all the way back into an embryonic-like stem cell. Those four factors are Oct4, Sox2, Klf4, and c-Myc, often abbreviated OSKM. A skin cell exposed to them long enough forgets it was ever a skin cell.

For aging research, that result was a tantalizing double-edged sword. On one hand, it proved that a cell’s biological age is not fixed. The information that makes a cell young is still present in an old cell; it has simply been buried under decades of epigenetic noise. On the other hand, full reprogramming is catastrophic in a living body. Erase a cell’s identity completely and you do not get rejuvenation, you get teratomas, the chaotic tumors that form when cells lose all sense of what they are supposed to be.

Partial reprogramming is the attempt to walk up to that cliff without falling off it. The idea, advanced in a landmark 2016 paper from Juan Carlos Izpisua Belmonte’s group at the Salk Institute and refined since, is to deliver reprogramming factors transiently, in short pulses, so that cells shed their accumulated epigenetic damage while still remembering they are skin, or muscle, or in this case retinal neurons. The cell gets younger without losing its job.

Life Biosciences took this principle and made two deliberate safety decisions. First, its Partial Epigenetic Reprogramming platform uses only three factors, Oct4, Sox2, and Klf4, the combination known as OSK. The fourth Yamanaka factor, c-Myc, is a well-known oncogene, and leaving it out removes one of the most dangerous ingredients. Second, the therapy is built around a controllable switch. The reprogramming genes are delivered inside an adeno-associated virus and kept silent until the patient takes the antibiotic doxycycline, which acts as a chemical on switch. Stop the doxycycline and the rejuvenation program shuts down. That control is the difference between an experiment and a therapy.

Why the Eye, and Why These Patients

The decision to launch in the eye is not incidental. It traces directly to a 2020 paper in Nature from Sinclair’s Harvard laboratory, led by Yuancheng Lu, titled "Reprogramming to recover youthful epigenetic information and restore vision." In that study, researchers used AAV-delivered OSK to rejuvenate retinal ganglion cells, the long-lived neurons that carry visual signals from the eye to the brain. In aged mice and in mice with optic nerve injury, the treatment promoted nerve regeneration and restored lost vision. Crucially, the benefit depended on enzymes that remove DNA methylation marks, the chemical tags that accumulate with age. The cells were not being rebuilt; their epigenetic clocks were being wound back.

That work became the scientific spine of ER-100. Life Biosciences then carried the approach into non-human primates. At the 2023 meeting of the Association for Research in Vision and Ophthalmology, and in later updates, the company reported that a single intravitreal injection of its OSK therapy, combined with daily systemic doxycycline, restored measurable visual function in monkeys given an injury designed to mimic non-arteritic anterior ischemic optic neuropathy, or NAION. NAION is a sudden, stroke-like loss of blood flow to the optic nerve that leaves people with permanent vision loss and has no approved treatment. Primates are a far higher bar than rodents, and clearing it is what gave the FDA enough confidence to allow a human study.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The Phase 1 trial, registered as NCT07290244, began in the first quarter of 2026. It is enrolling people with two age-related eye conditions: open-angle glaucoma, the most common form of glaucoma, and NAION. Both diseases damage retinal ganglion cells, the very neurons that responded to reprogramming in the animal studies. The study is small and cautious by design, focused first on safety, tolerability, and immune response, while also tracking multiple measures of visual function for early signs of benefit.

There are practical reasons the eye is an ideal proving ground for a technology this audacious. It is what immunologists call immune-privileged, meaning the body mounts a weaker immune attack against foreign material there, which lowers the risk that the AAV delivery vehicle will trigger dangerous inflammation. It is anatomically contained, so the therapy stays where it is injected rather than spreading through the body. And vision is exquisitely measurable. Ophthalmologists can quantify the smallest changes in visual fields, contrast sensitivity, and retinal structure, which means a subtle effect will not be missed. If you wanted to test whether you can safely rejuvenate human neurons, you could hardly design a better organ to start in.

The Theory Underneath the Therapy

ER-100 is also a clinical test of a specific and contested theory of why we age. Sinclair has argued for what he calls the information theory of aging. In this view, the body has two kinds of biological information. There is digital information, the DNA sequence itself, and there is analog information, the epigenome, which decides which genes are switched on or off in each cell. The theory holds that aging is primarily a loss of epigenetic information, a gradual corruption of the analog layer, rather than damage to the underlying genetic code.

His laboratory put that idea to a hard test in a 2023 paper in the journal Cell, describing a system the team called ICE, for inducible changes to the epigenome. By deliberately introducing and repairing DNA breaks, the researchers showed they could accelerate aging in mice without mutating their genes, then partially reverse the aged state with OSK reprogramming. The implication is striking. If aging is fundamentally a software problem, a loss of instructions rather than a corruption of the hardware, then a backup copy of the youthful instructions still exists inside old cells, and reprogramming is a way to restore it. ER-100 is, in effect, the first attempt to run that restore operation in a living person.

It is worth being clear that this theory is not settled science. Many aging biologists view epigenetic change as one driver among several, alongside DNA damage, mitochondrial decline, cellular senescence, and the loss of proteostasis. The clinical results from ER-100 will not resolve that debate, but they will provide something the field has never had: human safety data on whether you can manipulate the epigenetic clock of living neurons without harm.

The Risks Nobody Should Gloss Over

Enthusiasm here has to be matched by honesty about danger. Reprogramming is playing with the most basic property of a cell, its identity, and the history of the field is full of cautionary tales. Push reprogramming too far or for too long and cells can lose their specialized function or form tumors. That is precisely why the OSK-only formula, the transient doxycycline-controlled switch, and the contained delivery into the eye all exist. They are guardrails, not guarantees.

Independent scientists have urged appropriate caution. Stem cell biologist Paul Knoepfler of the University of California, Davis, who has tracked the reprogramming field closely, has described the ER-100 trial as both pioneering and genuinely risky, exactly the kind of first-in-human study that demands careful dose escalation and long follow-up. The honest summary is that the animal data are encouraging and the safety engineering is thoughtful, but no one yet knows how human retinal neurons will respond over months and years. A Phase 1 trial is designed to answer the most basic question, whether the therapy is safe, and nothing about early enrollment should be read as proof that it works.

There is also the matter of expectations. ER-100 targets specific eye diseases. It is not a general anti-aging treatment, it is not available outside the trial, and it does not validate any supplement, clinic, or product marketed under the banner of cellular rejuvenation. The leap from a controlled gene therapy injected into the eye under FDA oversight to a systemic therapy that rejuvenates the whole body remains enormous, and unproven.

Why This Moment Still Matters

Set against those caveats, the significance of the milestone is hard to overstate. For most of the past century, medicine has treated aging as a fixed backdrop, the stage on which specific diseases play out. Reprogramming represents a different philosophy, the idea that the aging process itself can be a target. ER-100 is the first time a regulator has allowed that idea to be tested directly in people. Whatever the outcome, the field now has a clinical foothold, a defined patient population, and a measurable endpoint. Other reprogramming programs, including efforts aimed at muscle, liver, and the broader nervous system, are watching closely, because the eye trial will shape what the FDA expects from everyone who follows.

The next few years will be telling. Phase 1 results, even preliminary safety readouts, will be among the most closely scrutinized data in longevity science. If ER-100 proves safe and shows even modest restoration of vision in people with untreatable optic nerve disease, it will validate two decades of work and open the door to reprogramming as a serious therapeutic strategy. If it stumbles, it will be a sober reminder of how far the gap remains between a rejuvenated mouse and a rejuvenated human.

What This Means For You

If you or someone you know is living with glaucoma or sudden optic nerve damage, the most important practical point is also the most restrained. ER-100 is in an early-stage safety trial enrolling a small number of patients at selected sites. It is not an approved treatment, and it will be years before anyone knows whether it helps. Standard, evidence-based care for these conditions, lowering eye pressure in glaucoma and managing vascular risk factors, remains the right path today. Anyone interested in trial participation should discuss it with an ophthalmologist and look at the official registry listing rather than acting on headlines.

For everyone watching the broader longevity field, the lesson is about calibration. This is a genuinely new kind of medicine reaching the clinic, and that is worth paying attention to. But the same news cycle that celebrates a reprogramming trial is also used to sell unregulated products that borrow its vocabulary. The presence of a single, carefully controlled gene therapy in a Phase 1 eye study says nothing about the safety or value of supplements, infusions, or clinics promising cellular rejuvenation. The most useful posture is interested patience: track the data as it emerges, respect the difference between a promising mechanism and a proven therapy, and keep doing the unglamorous things that already have decades of evidence behind them, regular exercise, good sleep, a diet rich in plants, and management of blood pressure, cholesterol, and blood sugar.

The arrival of ER-100 in human trials does not mean aging has been reversed. It means, for the first time, that the question of whether we can safely reset the biological age of human cells has moved from speculation to a clinical protocol with patients, endpoints, and oversight. That is a smaller claim than the headlines, and a far more durable one.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.